Equillium (EQ) Projected to Announce Earnings on Thursday

Equillium (NASDAQ:EQ) is projected to issue its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.0540) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 18, 2026 at 4:00 PM ET.

Equillium (NASDAQ:EQ) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). On average, analysts expect Equillium to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Equillium Stock Performance

NASDAQ EQ opened at $2.23 on Wednesday. The company has a market cap of $141.00 million, a P/E ratio of -6.97 and a beta of 1.82. The business’s 50 day moving average price is $2.70 and its 200-day moving average price is $2.22. Equillium has a fifty-two week low of $0.76 and a fifty-two week high of $3.54.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on EQ. Oppenheimer assumed coverage on Equillium in a research report on Thursday, April 23rd. They issued an “outperform” rating and a $7.00 price target for the company. Raymond James Financial reiterated a “strong-buy” rating and set a $7.00 price objective on shares of Equillium in a research report on Thursday, May 28th. Zacks Research downgraded shares of Equillium from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Wall Street Zen lowered shares of Equillium from a “hold” rating to a “sell” rating in a report on Saturday, June 27th. Finally, Clear Str raised shares of Equillium to a “strong-buy” rating in a research note on Tuesday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $7.57.

Insider Buying and Selling

In other Equillium news, insider Penny Tom sold 65,000 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $2.95, for a total value of $191,750.00. Following the transaction, the insider directly owned 65,000 shares in the company, valued at $191,750. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stephen Connelly sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $3.16, for a total transaction of $632,000.00. Following the transaction, the insider directly owned 793,000 shares in the company, valued at approximately $2,505,880. This trade represents a 20.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 406,392 shares of company stock valued at $1,224,898 in the last 90 days. Company insiders own 17.84% of the company’s stock.

Institutional Trading of Equillium

Large investors have recently modified their holdings of the company. Virtu Financial LLC increased its holdings in Equillium by 133.4% during the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after purchasing an additional 13,591 shares during the period. Millennium Management LLC purchased a new stake in shares of Equillium in the 3rd quarter worth $35,000. Royal Bank of Canada purchased a new stake in shares of Equillium in the 4th quarter worth $124,000. Persistent Asset Partners Ltd grew its position in shares of Equillium by 35.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 93,123 shares of the company’s stock worth $144,000 after buying an additional 24,132 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new position in shares of Equillium during the 3rd quarter worth $174,000. Hedge funds and other institutional investors own 27.05% of the company’s stock.

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.